These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
117 related articles for article (PubMed ID: 31156245)
1. [Efficacy, tolerability and safety of the treatment with teberif: the results of a 2-year randomized clinical trial of treatment naïve patients with remitting multiple sclerosis, who have not received DMT, after switching from other interferon β-1a]. Boyko AN; Bosenko LP; Vasilovskiy VV; Volkova LI; Zakharova MN; Kotov SV; Lekomtseva EV; Negrich TI; Parshina EV; Patrusheva OP; Prokopenko SV; Sazonov DV; Timchenko LV; Trinitatskiy YV; Khabirov FA; Khavunka MY; Chichanovskaya LV; Sherman MA; Ivanov RA; Lin'kova YN; Stukalina EY; Zinkina-Orikhan AV; Obukhova IG Zh Nevrol Psikhiatr Im S S Korsakova; 2019; 119(2. Vyp. 2):73-85. PubMed ID: 31156245 [TBL] [Abstract][Full Text] [Related]
2. [A comparative placebo-controlled clinical study on the efficacy and safety of interferon beta-1a for subcutaneous injections in patients with remitting multiple sclerosis: results of the first year of observations]. Boyko AN; Bosenko LP; Vasilovskiy VV; Volkova LI; Zakharova MN; Kotov SV; Lekomtseva EV; Negrich TI; Parshina EV; Patrusheva OP; Prokopenko SV; Sazonov DV; Timchenko PV; Trinitatskiy YV; Khabirov FA; Khavunka MY; Chichanovskaya LV; Sherman MA; Lin'kova YN; Zinkina-Orikhan AV; Tursunova KB Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(2. Vyp. 2):107-113. PubMed ID: 28617368 [TBL] [Abstract][Full Text] [Related]
3. Long-term efficacy and safety of intramuscular interferon beta-1a: Randomized postmarketing trial of two dosing regimens in Japanese patients with relapsing-remitting multiple sclerosis. Saida T; Kira J; Ueno Y; Harada N; Hirakata T Mult Scler Relat Disord; 2016 May; 7():102-8. PubMed ID: 27237769 [TBL] [Abstract][Full Text] [Related]
4. [The new pegylated interferon beta-1a (sampeginterferon beta-1a, BCD-054) in the treatment of remitting multiple sclerosis]. Boyko AN; Bakhtiyarova KZ; Dudin VA; Zaslavsky LG; Malkova NA; Parshina YV; Fedulov AS; Zinkina-Orikhan AV; Linkova YN; Ivanov RA; Chernovskaya TV Zh Nevrol Psikhiatr Im S S Korsakova; 2019; 119(10. Vyp. 2):100-109. PubMed ID: 31934995 [TBL] [Abstract][Full Text] [Related]
5. Neutralizing antibody production against Rebif® and ReciGen® in Relapsing-Remitting Multiple Sclerosis (RRMS) patients and its association with patient's disability. Shokrollahi Barough M; Ashtari F; Sadat Akhavi M; Asghari N; Mosayebi G; Mirmohammadkhani M; Kokhaei N; Bahraminia F; Ajami A; Kokhaei P Int Immunopharmacol; 2018 Sep; 62():109-113. PubMed ID: 29990690 [TBL] [Abstract][Full Text] [Related]
6. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis. La Mantia L; Di Pietrantonj C; Rovaris M; Rigon G; Frau S; Berardo F; Gandini A; Longobardi A; Weinstock-Guttman B; Vaona A Cochrane Database Syst Rev; 2016 Nov; 11(11):CD009333. PubMed ID: 27880972 [TBL] [Abstract][Full Text] [Related]
7. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Mikol DD; Barkhof F; Chang P; Coyle PK; Jeffery DR; Schwid SR; Stubinski B; Uitdehaag B; Lancet Neurol; 2008 Oct; 7(10):903-14. PubMed ID: 18789766 [TBL] [Abstract][Full Text] [Related]
8. Interferon beta 1a (Rebif®) in relapsing remitting multiple sclerosis. Sánchez RC; de la Fe AD; Suarez AP; Grass D; Vega TM; Canal AS; Siniscalco D; de Los Angeles Robinson Agramonte M Drug Dev Res; 2021 Aug; 82(5):707-715. PubMed ID: 33586209 [TBL] [Abstract][Full Text] [Related]
9. Natalizumab for relapsing remitting multiple sclerosis. Pucci E; Giuliani G; Solari A; Simi S; Minozzi S; Di Pietrantonj C; Galea I Cochrane Database Syst Rev; 2011 Oct; (10):CD007621. PubMed ID: 21975773 [TBL] [Abstract][Full Text] [Related]
10. Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. Khatri B; Barkhof F; Comi G; Hartung HP; Kappos L; Montalban X; Pelletier J; Stites T; Wu S; Holdbrook F; Zhang-Auberson L; Francis G; Cohen JA; Lancet Neurol; 2011 Jun; 10(6):520-9. PubMed ID: 21571593 [TBL] [Abstract][Full Text] [Related]
12. Subcutaneous recombinant interferon-beta-1a (Rebif): a review of its use in relapsing-remitting multiple sclerosis. Murdoch D; Lyseng-Williamson KA Drugs; 2005; 65(9):1295-312. PubMed ID: 15916455 [TBL] [Abstract][Full Text] [Related]
13. A randomized, multicentre, open-label, parallel-group trial of the tolerability of interferon beta-1a (Rebif) administered by autoinjection or manual injection in relapsing-remitting multiple sclerosis. Mikol D; Lopez-Bresnahan M; Taraskiewicz S; Chang P; Rangnow J; Mult Scler; 2005 Oct; 11(5):585-91. PubMed ID: 16193898 [TBL] [Abstract][Full Text] [Related]
14. Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial. Togha M; Karvigh SA; Nabavi M; Moghadam NB; Harirchian MH; Sahraian MA; Enzevaei A; Nourian A; Ghanaati H; Firouznia K; Jannati A; Shekiba M Mult Scler; 2010 Jul; 16(7):848-54. PubMed ID: 20488825 [TBL] [Abstract][Full Text] [Related]
15. Relapse outcomes, safety, and treatment patterns in patients diagnosed with relapsing-remitting multiple sclerosis and initiated on subcutaneous interferon β-1a or dimethyl fumarate: a real-world study. Ernst FR; Barr P; Elmor R; Wong SL Curr Med Res Opin; 2017 Dec; 33(12):2099-2106. PubMed ID: 28906152 [TBL] [Abstract][Full Text] [Related]
16. Spotlight on subcutaneous recombinant interferon-beta-1a (Rebif) in relapsing-remitting multiple sclerosis. Murdoch D; Lyseng-Williamson KA BioDrugs; 2005; 19(5):323-5. PubMed ID: 16207073 [TBL] [Abstract][Full Text] [Related]
17. Effect of interferon beta-1a subcutaneously three times weekly on clinical and radiological measures and no evidence of disease activity status in patients with relapsing-remitting multiple sclerosis at year 1. Traboulsee A; Li DKB; Cascione M; Fang J; Dangond F; Miller A BMC Neurol; 2018 Sep; 18(1):143. PubMed ID: 30217172 [TBL] [Abstract][Full Text] [Related]
18. The STAR Study: a real-world, international, observational study of the safety and tolerability of, and adherence to, serum-free subcutaneous interferon β-1a in patients with relapsing multiple sclerosis. Hupperts R; Ghazi-Visser L; Martins Silva A; Arvanitis M; Kuusisto H; Marhardt K; Vlaikidis N; Clin Ther; 2014 Dec; 36(12):1946-1957. PubMed ID: 24811754 [TBL] [Abstract][Full Text] [Related]
19. Interferon Beta-1a (AVONEX®) as a Treatment Option for Untreated Patients with Multiple Sclerosis (AXIOM): A Prospective, Observational Study. Kleinschnitz C; Niemczyk G; Rehberg-Weber K; Wernsdörfer C Int J Mol Sci; 2015 Jul; 16(7):15271-86. PubMed ID: 26154767 [TBL] [Abstract][Full Text] [Related]
20. [Experience of using genfaxon for treating patients with relapsing-remitting multiple sclerosis in the Russian Federation]. Bakhtiiarova KZ; Bragina OV; Vlasov IaV; Greshnova IV; Evdoshenko EP; Ivanishenkova EI; Kairbekova EI; Karnaukhova EN; Korotkevich NA; Leliukhina AV; Protasov IS; Rybina EV; Sazhnev AI; Skoromets AA; Soldatova OA; Trinitatskiĭ IuV; Fedianin AS; Chelnokova SN; Shabanova VD; Sharipova RR; Shchegol'kova EA; Iampol'skaia-Gosteva IA Zh Nevrol Psikhiatr Im S S Korsakova; 2014; 114(8):39-45. PubMed ID: 25345629 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]